Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Merck Buys Animal Health Company Antelliq

Merck & Co. is paying about $2.4 billion to acquire all outstanding shares of Antelliq Group, and is also assuming the digital technology company’s debt of $1.3 billion.

Read More »

Amgen Terminates $540 Million Deal with Advaxis

Shares of Advaxis plunged more than 28 percent in premarket trading after the company quietly disclosed that Amgen terminated their collaboration on an immuno-oncology program.

Read More »

J&J shares nosedive on report company knew of asbestos in baby powder

Shares of Johnson & Johnson tumbled 12 percent after Reuters reported that the pharma major knew for decades that cancer-causing asbestos lurked in the company’s Baby Powder.

Read More »

Mylan says Sanofi loses Lantus insulin patent claims

U.S. generics drugmaker Mylan said the United States Patent and Trademark Office rejected Sanofi’s infringement claims relating to insulin drug Lantus.

Read More »

Mobile Marketing Special Feature: Growing voice for mobile

Pharma continues to lag behind the consumer space in the use of mobile marketing technologies, but the steady advance of consumer tech giants Google and Amazon into the healthcare space means that the industry will have to adapt the tools of AI, voice and chatbots into their marketing, just as their consumer brethren already have.

Read More »

Mobile Marketing Special Feature: Getting pharma into new mobile tech

Intouch Solutions’ Sean Hartigan and Heartbeat’s David Sakadelis say their pharma clients are skittish about the use of chatbots and AI, with an understanding of these technologies more influenced by the grim future of Skynet in the “Terminator” movie franchise rather than the reality of where AI is right now.

Read More »

Mobile Marketing Special Feature: Still a case for apps

In the initial excitement over the possibilities of mobile marketing, pharma rushed to create its own apps. And then these apps languished.

Read More »

Why Type One Diabetes Patients Need Closed Loop Insulin Systems

For a while now there has been a heated debate surrounding hybrid and closed loop insulin systems.

Read More »

Tivity Health to buy Nutrisystem for $1.4 billion

Tivity Health Inc. said the company would acquire Nutrisystem Inc. in a cash-and-stock deal that values the weight management product developer at $1.4 billion.

Read More »

Gilead Sciences snares Roche veteran O’Day as CEO

Drugmaker Gilead Sciences Inc. named Roche Holding AG’s Daniel O’Day as the company’s new chief executive, tapping an industry veteran to fill a management vacuum.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom